Roche says arthritis drug Actemra successful in phase III study |
|
|
|
Published
:
Tue, 10 Jul 2007 07:54
|
ZURICH (Thomson Financial) - Roche Holdings AG said that arthritis drug Actemra has proved successful in a phase III clinical study evaluating the effectiveness of the drug in patients with difficult-to-treat rheumatoid arthritis (RA).The Radiate study was conducted over 24 weeks with 498 patients with difficult-to-treat RA.'The greater proportion of patients treated with Actemra plus methotrexate, achieved a significant improvement in disease signs and symptoms,' Roche said.The Radiate study focused on patients with moderate to severe active RA whose joints are significantly more affected by the disease.sarah.fenwick@thomson.comsf/cm2COPYRIGHTCopyright AFX News Limited 2007. All rights reserved.The copying, republication or redistribution of AFX News Content, including by framing or similar means, is expressly prohibited without the prior written consent of AFX News.
|
|
|
|
|
|
|
| Stock
Quotes * |
|
NASDAQ
|
|
1754.88 |
-108.08 (
-5.79 %)
|
| SYMBOL (
2008-10-08 ) |
| LAST |
CHANGE
|
|
WHITBREAD
(
7:00am )
|
|
1014.00 |
+57.00 (
6.16 %)
|
|
NEXT
(
7:00am )
|
|
1110.00 |
+51.00 (
5.07 %)
|
|
HBOS
(
7:00am )
|
|
141.90 |
+47.90 (
50.96 %)
|
| SYMBOL (
2008-10-07 )
|
| LAST |
CHANGE
|
|
INTEL CP
(
4:00pm ) |
|
16.02 |
-0.91 (
-5.33 %)
|
| SYMBOL (
2008-10-07 )
|
| LAST |
CHANGE
|
|
|
Print this Story
Roche's arthritis drug Actemra reaches goal in 2nd phase III study 